- Home
- ALDX vs TLSI Comparison
ALDX vs TLSI Comparison
Compare ALDX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALDX | TLSI |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.7M | 267.1M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALDX | TLSI |
|---|---|---|
| Price | $1.57 | $4.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 6.0M | 165.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $3.42 |
| 52 Week High | $6.18 | $7.95 |
Technical Indicators
Market Signals| Indicator | ALDX | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 28.62 | 47.19 |
| Support Level | $1.07 | $3.51 |
| Resistance Level | $5.75 | $5.47 |
| Average True Range (ATR) | 0.21 | 0.24 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 21.88 | 75.36 |
Price Performance
Historical ComparisonAbout ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.